Table: AnGes MG -Q1 group results
Apr 24 (Reuters)-
AnGes MG Inc
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2017 Mar 31, 2016 Dec 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 83 mln 83 mln 360 mln
(+0.1 pct) (+1.6 pct)
Operating loss 1.04 loss 1.18 loss 3.40
Recurring loss 1.03 loss 1.23 loss 3.40
Net loss 1.51 loss 1.23 loss 3.40
EPS loss 20.89 yen loss 21.75 yen loss 46.99 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - AnGes MG Inc.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001